These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28111425)

  • 1. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
    Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
    Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
    Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
    Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
    Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
    Maezawa T; Yonese J; Tsukamoto T; Ishii N; Fukui I
    Nihon Hinyokika Gakkai Zasshi; 2002 Nov; 93(7):727-35. PubMed ID: 12494517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer.
    Kawamata H; Yamashita K; Nakamura K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Kumamoto Y; Watanabe M
    Anticancer Res; 2013 Feb; 33(2):583-94. PubMed ID: 23393352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
    Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy.
    Huo YR; Huang Y; Liauw W; Zhao J; Morris DL
    Anticancer Res; 2016 Mar; 36(3):1041-9. PubMed ID: 26976996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
    Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
    Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
    Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
    Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
    Okano N; Kasuga A; Kawai K; Yamauchi Y; Kobayashi T; Naruge D; Nagashima F; Furuse J
    Anticancer Res; 2018 Mar; 38(3):1755-1761. PubMed ID: 29491113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
    Kim YJ; Im SA; Kim HG; Oh SY; Lee KW; Choi IS; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Kim SW; Heo DS; Yoon YB; Bang YJ
    Ann Oncol; 2008 Jan; 19(1):99-103. PubMed ID: 17846018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.